

Elekta convertible bond and new financing

STOCKHOLM, March 29, 2017 – Elekta's (EKTA-B.ST) convertible bond matures on April 25 and the last day for conversion into shares was March 28. Approximately SEK 1,825 million has not been converted and will therefore be repaid to the convertible bond holders.

In order to secure financing, Elekta has issued a SEK 1 billion bond, with five year maturity, under the existing Medium Term Note Program with a total limit of SEK 5 billion. The interest rate on the bond is three months STIBOR plus an interest margin of 1.75 percent that is paid quarterly. Final terms are available on Elekta's website <u>www.elekta.com</u>. Danske Bank and SEB have acted as lead managers for the issue.

Elekta has also entered into a five-year loan agreement of GBP 90 million with the Nordic Investment Bank with the purpose of financing R&D investments.

###

For further information, please contact:

Håkan Bergström, CFO, Elekta AB Tel: +46 8 587 25 547, e-mail: <u>hakan.bergstrom@elekta.com</u> Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communications, Elekta AB Tel: +46 722 215 017, e-mail: <u>tobias.bulow@elekta.com</u> Time zone: CET: Central European Time

About Elekta

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com